- New Global Arrayed Protein Stability Analysis (GAPSA) can help identify HIV circuits that drive the destruction of healthy human proteins in cells.
- HIV-1 accessory proteins Vpu usually degrade human proteins to enhance its infection process.
- Identifying Vpu target proteins can help find new drugs that block the interaction, potentially preserve host anti-viral proteins and limit HIV infection.
Genome-scale imaging-based approach may prevent HIV from degrading human proteins to develop a stronghold, finds a new study. The findings of this study are published in the Cell Reports
The platform, termed Global Arrayed Protein Stability Analysis (GAPSA), enables the identification of circuits that drive the destruction of proteins in cells and has broad application to identify novel therapeutic targets for diseases such as Alzheimer's disease, cancer, autoimmune disorders and infectious disease.
‘Global Arrayed Protein Stability Analysis (GAPSA) can be used to find host proteins targeted by the HIV-1 accessory protein Vpu, which allows the virus to replicate. Identifying these proteins can help find new drugs that can potentially limit HIV infection.’
"We have used GAPSA to find host proteins targeted by the HIV-1 accessory protein Vpu, which allows the virus to replicate," says Sumit Chanda, Ph.D., director, and professor of the Immunity and Pathogenesis Program at SBP and senior author of the study. "We selected Vpu as a test case because although some Vpu targets were known, we suspected there were more. Indeed, GAPSA was able to pinpoint several host proteins with the anti-viral activity that had not been reported in connection with HIV."
Vpu is HIV's weapon against the innate immune response--the body's first line of defense against pathogens. Vpu triggers the degradation of host proteins meant to protect against HIV infection, thereby helping the virus overcome barriers to infection and replication.
"In this study we screened a set of 433 interferon-stimulated genes (ISGs)--genes that become activated in response to infection--against Vpu to create a more comprehensive list of HIV's cellular targets," says Lars Pache, Ph.D., staff scientist in Chanda's lab and co-author of the paper.
"Identifying Vpu target proteins creates an opportunity to find new drugs that block the interaction, potentially preserving host anti-viral proteins and limiting HIV infection. Importantly, the system can be equally applied to other infectious diseases that evade the immune system, such as Ebola, influenza, Zika, and others," explains Pache.
"To our knowledge, GASPA is the first cell-based array platform that screens for regulators of the building and turnover of proteins (proteostasis). In addition to providing critical knowledge of how cells work, the technology can be applied to identify protein degraders that specifically target disease-causing proteins, which can open new therapeutic opportunities for a multitude of diseases," says Chanda.
"For example, in cancer, we can ask which proteins specifically degrade or destabilize oncoproteins, such as RAS and myc, and look for ways (drugs) to enhance that interaction. Similarly, with Alzheimer's disease, we can screen for proteins that degrade beta-amyloid and create therapeutic strategies to discretely control the process without disrupting the entire cellular degradation machinery.
"Our next step(s) is to collaborate with scientists across other disease areas to identify these molecular circuits that regulate protein stability," Chanda says. "We plan to use the technology to comprehensively catalog pairs of all human proteins known to regulate degradation and their cellular targets. We anticipate that this compendium of activities will expand the therapeutic landscape for many diseases."
- Prashant Jain, Guney Boso, Simon Langer,et.al.Large-Scale Arrayed Analysis of Protein Degradation Reveals Cellular Targets for HIV-1 Vpu, Cell Reports (2018).DOI: https://doi.org/10.1016/j.celrep.2018.01.091 Link